LONDON (Reuters) - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.
The agreement gives the U.S. drugmaker an exclusive option to the Danish biotech firm's therapeutic prostate cancer vaccine Prostvac and signals that such shots may have a bright future when combined with so-called checkpoint inhibitor drugs.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21
16:37 Fitbit acquires software assets from rival Pebble12
14:31 Lost Christmas parcels 'prompt two-and-a-half-hour hunt'14
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19